HLYK HealthLynked Corporation (QB)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 15, 2025

 

HealthLynked Corp.

(Exact name of registrant as specified in charter)

 

Nevada		000-55768		47-1634127
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

1265 Creekside Parkway, Suite 302, Naples FL 34108

(Address of principal executive offices)

 

(800) 928-7144

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Chief Financial Officer 

 

Effective January 15, 2025, HealthLynked Corp., a Nevada corporation (the “Company”), appointed Jeremy Daniel, age 48, as its part-time Chief Financial Officer, effective immediately. Mr. Daniel has also served as Chief Financial Officer for Innoveren Scientific, a publicly traded biotech firm, since 2019.

 

Before his time at Innoveren, Mr. Daniel held the positions of Chief Financial Officer at Regenerative Medicine Solutions (2013-19) and at Sleep Apnea Treatment Centers of America, and Controller for Omnicare (2012-14).

 

Mr. Daniel holds a Master of Business Administration in Business Administration from Xavier University and a Bachelor of Business Administration and Accounting from The University of Cincinnati. Mr. Daniel is also a Certified Public Accountant.

 

The Company and Mr. Daniel have agreed that Mr. Daniel will work two days per week and his base salary will be $66,000 per year.

 

There are no arrangements or understandings between Mr. Daniel and any other person pursuant to which he was selected for his position. In addition, there are no family relationships between Mr. Daniel and any directors or executive officers of the Company, and no transactions are required to be reported under Item 404(a) of Regulation S-K between Mr. Daniel and the Company.

 

Departure of Chief Financial Officer 

 

Effective January 15, 2025, David Rosal tendered his resignation as Chief Financial Officer of the Company. Mr. Rosal’s resignation is not a result of any disagreement between himself and the Company, its management, the Company’s Board of Directors (the “Board”) or any committee of the Board. The Company appreciates Mr. Rosal’s diligent service as Chief Financial Officer.

 

Item 7.01 Regulation FD Disclosure.

 

Furnished as Exhibit 99.1 of this Current Report on Form 8-K is a press release issued by the Company with regard to Mr. Daniel’s appointment as Chief Financial Officer. The press release shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

 

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit No.		Exhibit Title or Description
99.1		Press Release dated January 15, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

	HEALTHLYNKED CORP.
Date: January 15, 2025	/s/ Michael Dent
	Michael Dent
	Chief Executive Officer and Chairman

 

 

3

Exhibit 99.1

 

HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer

 

NAPLES, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare technology solutions, is proud to announce the appointment of Jeremy Daniel as its new Chief Financial Officer (CFO), effective immediately. With an impressive career spanning over two decades, Mr. Daniel brings exceptional expertise in financial management, strategic planning, and organizational development.

 

As CFO, Jeremy will oversee HealthLynked’s financial strategy and operations, driving growth, operational efficiency, and shareholder value. His appointment underscores HealthLynked’s commitment to strengthening its executive leadership as the company continues to innovate and expand its healthcare technology solutions.

 

Jeremy Daniel has built a stellar reputation as a results-driven executive in diverse industries including healthcare, biotechnology, and finance. Most recently, he served as CFO for Innoveren Scientific, a publicly traded biotech firm, where he successfully led acquisitions, improved financial systems, and implemented strategic initiatives that fueled the company’s growth and operational success. His achievements include raising over $100M in funding through public and private equity markets and executing pivotal mergers and acquisitions.

 

Michael Dent, M.D., CEO of HealthLynked, shared his enthusiasm for the appointment: “Jeremy’s extensive experience and proven leadership in financial operations and strategic planning make him an outstanding addition to the HealthLynked team. His track record of optimizing financial performance and supporting organizational growth aligns perfectly with our vision to revolutionize healthcare through technology.”

 

On accepting the position, Mr. Daniel expressed his excitement about the opportunity to contribute to HealthLynked’s mission: “Joining HealthLynked at this transformative time is a true honor. I am excited to leverage my experience to enhance financial strategies, foster innovation, and support the company’s efforts in improving patient outcomes and healthcare connectivity.”

 

With a career that has included roles as CFO for Regenerative Medicine Solutions and controller for Omnicare, Mr. Daniel is well-versed in leading financial systems in compliance with GAAP and SEC regulations. A Certified Public Accountant (CPA) and holder of an MBA from Xavier University, his credentials position him to lead with precision and integrity.

 

About HealthLynked Corp.

 

HealthLynked is dedicated to transforming healthcare by leveraging technology to connect patients and providers. Its cloud-based HealthLynked Network empowers patients to manage their medical information securely while enabling providers to optimize care and operations. Through innovation and collaboration, HealthLynked aims to create a more efficient and patient-centric healthcare system. For more information, visit www.healthlynked.com.

 

Download the HealthLynked App

 

·

Apple App Store

 

·

Google Play Store

 

 

Forward-Looking Statements

 

Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, including as a result of any acquisitions, performance, or achievements, may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would,” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management and us, are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information, or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the “Risk Factors” section of our most recent Annual Report on Form 10-K and in other filings we have made with the U.S. Securities and Exchange Commission. These reports are publicly available at www.sec.gov.

 

Contact Information:

 

Mike Paisan

 

Director of Investor Relations

 

HealthLynked Corp.

1265 Creekside Pkwy, Suite 301

Naples, Florida 34108

Phone: 1-800-928-7144

Email: IR@healthlynked.com

 

 

 

v3.24.4

Cover	Jan. 15, 2025
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 15, 2025
Entity File Number	000-55768
Entity Registrant Name	HealthLynked Corp.
Entity Central Index Key	0001680139
Entity Tax Identification Number	47-1634127
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	1265 Creekside Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Naples
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34108
City Area Code	800
Local Phone Number	928-7144
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

---